Prelude Therapeutics Inc
NASDAQ:PRLD
Prelude Therapeutics Inc
NASDAQ:PRLD
Price:
4.22
USD
-4.09%
Market Closed
Market Cap:
$265.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
US |
|
C
|
Climate Transition Capital Acquisition I BV
AEX:CTCA1
|
NL |
Balance Sheet
Balance Sheet Decomposition
Prelude Therapeutics Inc
Prelude Therapeutics Inc
Balance Sheet Decomposition is not available for
Prelude Therapeutics Inc
Prelude Therapeutics Inc
Balance Sheet
Prelude Therapeutics Inc
Prelude Therapeutics Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
16
|
19
|
218
|
32
|
31
|
25
|
12
|
35
|
|
| Cash Equivalents |
16
|
19
|
218
|
32
|
31
|
25
|
12
|
35
|
|
| Short-Term Investments |
0
|
0
|
0
|
259
|
171
|
208
|
121
|
68
|
|
| Other Current Assets |
0
|
1
|
3
|
4
|
3
|
3
|
2
|
2
|
|
| Total Current Assets |
16
|
20
|
221
|
295
|
204
|
236
|
136
|
106
|
|
| PP&E Net |
1
|
2
|
3
|
6
|
7
|
38
|
35
|
32
|
|
| PP&E Gross |
1
|
2
|
3
|
6
|
7
|
38
|
35
|
32
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
2
|
3
|
4
|
5
|
7
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
4
|
9
|
4
|
4
|
3
|
|
| Total Assets |
16
N/A
|
22
+34%
|
224
+921%
|
305
+36%
|
221
-28%
|
278
+26%
|
176
-37%
|
141
-19%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
2
|
4
|
8
|
7
|
5
|
8
|
4
|
|
| Accrued Liabilities |
1
|
2
|
7
|
11
|
14
|
16
|
17
|
14
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
35
|
|
| Total Current Liabilities |
2
|
5
|
11
|
19
|
22
|
22
|
26
|
53
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
3
|
19
|
18
|
18
|
|
| Total Liabilities |
3
N/A
|
5
+92%
|
11
+138%
|
19
+68%
|
25
+31%
|
41
+62%
|
44
+9%
|
73
+65%
|
|
| Equity | |||||||||
| Common Stock |
37
|
66
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
23
|
51
|
107
|
219
|
335
|
456
|
584
|
683
|
|
| Additional Paid In Capital |
0
|
1
|
320
|
506
|
532
|
693
|
715
|
752
|
|
| Other Equity |
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
|
| Total Equity |
14
N/A
|
17
+22%
|
212
+1 148%
|
286
+35%
|
195
-32%
|
237
+21%
|
131
-45%
|
69
-48%
|
|
| Total Liabilities & Equity |
16
N/A
|
22
+34%
|
224
+921%
|
305
+36%
|
221
-28%
|
278
+26%
|
176
-37%
|
141
-19%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
4
|
4
|
44
|
48
|
48
|
55
|
55
|
63
|
|
Switch to:
Switch to:
See Also
Discover More
